Findings

What do systematic reviews say?

4,919 questions · 13,869 findings · 2,177 reviews · Headline outcomes only

Sort:Best matchNewestHighest certainty Download CSV

No studies found 13,869 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Standard‐protein formula vs low‐protein formula

All‐cause mortality · healthy, full‐term (37 to 42 weeks), formula‐fed infants

The review found no eligible studies for this question.

1 finding from 1 review

Higher versus lower protein intake in formula‐fed term infants 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐protein formula vs standard‐protein formula

All‐cause mortality · healthy, full‐term (37 to 42 weeks), formula‐fed infants

The review found no eligible studies for this question.

1 finding from 1 review

Higher versus lower protein intake in formula‐fed term infants 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class I and/or III antiarrhythmics vs control

Outcomes at > 3 to 6 months after ablation · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class I antiarrhythmics vs control

Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class I antiarrhythmics vs control

Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class I antiarrhythmics vs control

Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class I antiarrhythmics vs control

All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class III antiarrhythmics vs control

Outcomes at > 3 to 6 months after ablation · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class III antiarrhythmics vs control

Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class III antiarrhythmics vs control

Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class I and/or III antiarrhythmics vs control

Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Class I antiarrhythmics vs control

Outcomes at > 3 to 6 months after ablation · Human trial participants undergoing ablation for atrial fibrillation

The review found no eligible studies for this question.

1 finding from 1 review

Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Psychological interventions vs active comparators

Anxiety (adverse effect, post‐intervention) · adults (aged 16 years and over) with CF

The review found no eligible studies for this question.

1 finding from 1 review

Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Psychological interventions vs active comparators

Treatment‐related adverse events Depression · adults (aged 16 years and over) with CF

The review found no eligible studies for this question.

1 finding from 1 review

Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Single foetal haemoglobin inducer at any dose or duration vs placebo or usual care

Frequency of transfusion (transfused volume/year) · people with non‐transfusion‐dependent β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Single foetal haemoglobin inducer at any dose or duration vs another foetal haemoglobin inducer

QoL · people with non‐transfusion‐dependent β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Single foetal haemoglobin inducer at any dose or duration vs another dose or dose regimen of the same foetal haemoglobin inducer

Frequency of transfusion (transfused volume/year) · people with non‐transfusion‐dependent β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Single foetal haemoglobin inducer at any dose or duration vs another dose or dose regimen of the same foetal haemoglobin inducer

Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Single foetal haemoglobin inducer at any dose or duration vs another dose or dose regimen of the same foetal haemoglobin inducer

QoL · people with non‐transfusion‐dependent β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Single foetal haemoglobin inducer at any dose or duration vs placebo or usual care

Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found